Structural basis for phosphorylation and lysine acetylation cross-talk in a kinase motif associated with myocardial ischemia and cardioprotection by Parker, Benjamin L. et al.
Structural Basis for Phosphorylation and Lysine Acetylation
Cross-talk in a Kinase Motif Associated with Myocardial
Ischemia and Cardioprotection*□S
Received for publication, February 4, 2014, and in revised form, June 29, 2014 Published, JBC Papers in Press, July 9, 2014, DOI 10.1074/jbc.M114.556035
Benjamin L. Parker‡§¶1, Nicholas E. Shepherd2, Sophie Trefely§, Nolan J. Hoffman§¶, Melanie Y. White**2,
Kasper Engholm-Keller**, Brett D. Hambly‡**, Martin R. Larsen‡‡, David E. James§¶**, and Stuart J. Cordwell‡**3
From the ‡Discipline of Pathology, School of Medical Sciences, University of Sydney, Sydney 2006, Australia, the §Diabetes and
Obesity Program, ¶Biological Mass Spectrometry Unit, Garvan Institute of Medical Research, 2010 Australia , the School of
Molecular Bioscience and the **Charles Perkins Centre, University of Sydney, Sydney 2006, Australia, and the ‡‡Department of
Biochemistry andMolecular Biology, University of Southern Denmark, Campusvej 55, 5230 Odense M, Denmark
Background: Myocardial ischemia and cardioprotection induce signal networks mediated by post-translational
modification.
Results: Phosphorylation sites altered by ischemia and/or cardioprotection were influenced by inhibition of lysine acetylation
consistent with cross-talk.
Conclusion: Lysine acetylation induces proximal dephosphorylation in a kinase motif by salt bridge inhibition.
Significance: Cross-talk is likely to be an important aspect of signaling during ischemia and cardioprotection.
Myocardial ischemia and cardioprotection by ischemic pre-
conditioning induce signal networks aimed at survival or cell
death if the ischemic period is prolonged. These pathways are
mediated by protein post-translational modifications that are
hypothesized to cross-talk with and regulate each other. Phos-
phopeptides and lysine-acetylated peptides were quantified in
isolated rat hearts subjected to ischemia or ischemic pre-condi-
tioning, with and without splitomicin inhibition of lysine
deacetylation. We show lysine acetylation (acetyl-Lys)-depen-
dent activationofAMP-activatedprotein kinase,AKT, andPKA
kinases during ischemia. Phosphorylation and acetyl-Lys sites
mapped onto tertiary structures were proximal in>50% of pro-
teins investigated, yet they were mutually exclusive in 50
ischemic pre-conditioning- and/or ischemia-associated pep-
tides containing the KXXS basophilic protein kinase consensus
motif. Modifications in this motif were modeled in the C termi-
nus of muscle-type creatine kinase. Acetyl-Lys increased proxi-
mal dephosphorylation by 10-fold. Structural analysis of modi-
fied muscle-type creatine kinase peptide variants by two-
dimensional NMR revealed stabilization via a lysine-phosphate
salt bridge, which was disrupted by acetyl-Lys resulting in back-
bone flexibility and increased phosphatase accessibility.
Prolonged blockage of coronary blood flow (ischemia), even
with subsequent restoration (reperfusion), may result in
cardiomyocyte apoptosis and necrosis. Ischemia/reperfusion
(I/R)4 thus represents a significant clinical burden. IPC, a series
of short I/R cycles prior to extended ischemia, elicits a degree of
cardioprotection against I/R injury. The oxygen supply/de-
mand imbalance upon ischemia reduces oxidative metabolism
and results in depletion of intracellular ATP accompanied by a
time-dependent rise inAMP.Anaerobiosis also generates pyru-
vate conversion to lactate to maintain oxidized NAD levels,
which leads to intracellular acidosis and promotes Na and
Ca2 overload (1, 2). Activation of signal pathways in ischemia
and IPC is established (3, 4) and includes mitogen-activated
protein kinases (MAPKs) (5), protein kinase C (PKC) (6–8),
phosphatidylinositol 3-hydroxykinase/AKT (PI3K/AKT) (9),
and cyclic AMP-dependent protein kinase A (PKA) (10, 11).
The ischemia-associated increase inAMP:ATP also activates
a network initiated in part by AMP-activated protein kinase
(AMPK). AMPK regulates fatty acid metabolism, where
AMPK-mediated phosphorylation inactivates acetyl-CoA car-
boxylase (ACC) resulting in a decrease in cytosolic malonyl-
CoA (12) and an increase in fatty acid uptake and oxidation in
the mitochondria (13–15). AMPK activation also modulates
energy consumption (16), cell survival, and regulation of the
fuel-sensing sirtuin (SIRT) family of protein deacetylases (17).
AMPK and SIRT1 regulate each other, which suggests an
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AMPK/SIRT1 sensing cycle with phosphorylation/acetylation
cross-talk on common substrates (18). The SIRTs are a family of
seven NAD-dependent enzymes, whose activity is influenced
by cellular energy and redox status (19). SIRT1 overexpression
confers myocardial protection during oxidative stress (20) and
prevents apoptosis via p53 inactivation (21), whereas splitomi-
cin-mediated inhibition of SIRT1 attenuates IPC (22), which
collectively provides strong evidence that lysine acetylation
(acetyl-Lys)/deacetylation contributes to cardioprotection and
cell survival during ischemia.
Post-translational modification (PTM) cross-talk is best
exemplified in the “chromatin code” (23–26). Cross-talk can
include the following: (i) competitive modification of the same
site; (ii) modification influencing additional PTM at a proximal
site; or (iii) a PTM activating/deactivating the modifying
enzyme for a second modification. Studies of histone PTM
cross-talk identified a modification that subsequently resulted
in the alteration of a secondary cis (intramolecular) modifica-
tion, i.e. phosphorylation of Ser-10 on histone H3 increases
acetylation of Lys-14 (27, 28). This process was also observed at
a trans (inter-molecular) level, i.e. ubiquitylation of histone
H2B stimulates histone H3 methylation (29). Cross-talk can
also influence PTM kinetics (30–33). Alternatively, PTMsmay
activate/deactivate modifying enzymes, including (de)acetyla-
tion of kinases (34–37), for example SIRT1 promotion of AKT
activity (38), (de)phosphorylation of deacetylases/acetyltrans-
ferases (39–42), or a PTM-modifying enzyme regulating global
levels of another PTM (43, 44). Cross-talk between phosphory-
lation and acetyl-Lys can include the recruitment of kinases/
phosphatases by acetyl-Lys (45, 46), the recruitment of histone
deacetylases/acetyltransferases by phosphorylation (47–49), or
where either phosphorylation or acetyl-Lys is required for the
other to occur at a proximal site (50). Examples of site-specific
competition include the following: between acetylation and
phosphorylation of serine in the activation loop of MAP2K6
(51); O-GlcNAcylation and phosphorylation of Thr-58 in
c-Myc (52); Ser-1177 in endothelial nitric-oxide synthase (53);
and Ser-733 in IKK (54).
Peptide-centric enrichment combinedwith quantitative tan-
dem mass spectrometry (MS/MS) has become the gold stand-
ard for generating global phosphopeptide profiles under a
variety of stimuli anddisease states (55–57), although antibody-
based enrichment of acetylated peptides followed by MS/MS
has also proven successful (58–63). We utilized sequential
enrichment to globally quantify phosphorylated and lysine-
acetylated peptides in isolated rat hearts subjected to ischemia
and IPC, in the presence or absence of splitomicin inhibition of
lysine deacetylation, using isobaric labeling andMS/MS. These
data enabled an evaluation of sequence motifs displaying evi-
dence of PTM cross-talk, which showed that phosphorylation
and acetyl-Lys are mutually exclusive in 50 ischemia/IPC-reg-
ulated peptides containing a basophilic protein kinase motif
(KXXS).Wedetermined the rates of cross-talk between PTM in
the C-terminal region of muscle-type creatine kinase (CKM)
and demonstrated the formation of a phosphate-lysine salt
bridge. Acetyl-Lys disrupts the phosphate-lysine interaction
and results in increased de-phosphorylation at this site.
EXPERIMENTAL PROCEDURES
Rat Heart Isolation—Male Lewis rats (200 g) were eutha-
nized with an intraperitoneal injection of sodium pentobarbital
(0.5 mg/g; University of Sydney Animal Ethics Committee
approval K20/6-2009/3/5078). The aorta was cut1 cm above
the aortic valve; the heart removed was and placed in ice-cold
saline solution (0.9% (w/v)NaCl, pH7.4).Heartswere subjected
to Langendorff perfusion using oxygenated Krebs-Henseleit
buffer (118mMNaCl, 25mMNaHCO3, 1.2mMKH2PO4, 4.8mM
KCl, 1.2 mM MgSO4, 11 mM glucose, 2.0 mM CaCl2, pH 7.4) at
37 °C, as described (64). Heart rates and left ventricular devel-
oped pressure (LVDP) were recorded (LabChart, ADInstu-
ments, Bella Vista, Australia) and measured as a rate pressure
product (RPP; beats/minLVDP inmmHg). For ischemia and
IPC, hearts were equilibrated for a baseline period of 15 min
with normoxic perfusion and then assigned to 12 groups as
follows: (i) 0 min; (ii) 2 min; (iii) 10 min; and (iv) 20 min of
no-flow ischemia (n  3 for each time point); (v) 0 min; (vi) 2
min; (vii) 10 min; and (viii) 20 min of no-flow ischemia follow-
ing 15 min of equilibration with 10 M splitomicin (n  3 for
each time point); (ix) acute IPC with three 2-min cycles of I/R
(n 3); (x) acute IPC with three 2-min I/R following 15 min of
equilibration with 10 M splitomicin (n  3); (xi) 20 min of
normoxic perfusion (n 3); and (xii) 20 min of normoxic per-
fusion with 10 M splitomicin. Hearts were snap-frozen and
stored at80 °C. All hearts achieved a, RPP of 25,000 (5000),
a flow rate of 9 ml/min, and a perfusion pressure of 80 mm Hg
at the end of the baseline period. Myocardial function was
determined by comparing the RPP for additional hearts sub-
jected to 20min of ischemia, followed by 30min of reperfusion,
to allow determination of functional recovery. The extent of
necrosis was determined by staining hearts with triphenyltetra-
zolium chloride (64). Following normoxic perfusion, no signif-
icant difference in the functional performance of the hearts was
observed (RPP  92.2% of baseline; see supplemental Fig. S1).
Hearts subjected to 20 min of ischemia and 30 min of reperfu-
sion showed loss of hemodynamic performance (RPP30%
of baseline; p value 	0.05) and evidence of necrosis (17.8 
3.6% negative triphenyltetrazolium chloride staining of left
ventricular mass compared with 0.4 0.1% for baseline hearts)
(supplemental Fig. S1). Splitomicin had no significant effect on
normoxic heart function, as reported (22).
Cell Culture—Rat L6 myoblasts were 2-plex SILAC-labeled
in -minimal essential medium containing 5.5 mM glucose
(Invitrogen) and 10% fetal bovine serum (Hyclone, Logan UT).
Following five passages, cells at 80% confluence were trans-
fected with Lipofectamine-2000 and 15 g of plasmid DNA.
The plasmid consisted of human CKM cloned into a pCMV5
plasmid containing an N-terminal FLAG tag and was gener-
ously provided by Prof. Yong-Bin Yan and Prof. Hai-Meng
Zhou (School of Life Sciences, Tsinghua University, China).
Site-directed mutagenesis was performed with the QuikChange
site-directed mutagenesis kit (Invitrogen) to generate a K369Q
acetyl-Lys mimic and an S372E phospho-mimic using the
primers 5GAGAAGAAGTTGGAGCAAGGCCAGTCC-
ATCG and 5GAAGTTGGAGAAAGGCCAGGAAATCGA-
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CGACATGATCCCCG, respectively. Cells were transfected
for 24 h and harvested after an additional 24 h.
Myocardial Peptide Preparation—Myocardial tissue was
ground under liquid nitrogen, and 100 mg of powdered tissue
from each group was pooled (i.e. n 3, total 300 mg). Samples
were homogenized in 3-fold the weight (i.e. 1 mg/3 l) of lysis
buffer (20 mM Tris, 1 mM dithiothreitol (DTT), 0.5% SDS, pro-
tease inhibitor mixture (Roche Applied Science), phosphatase
inhibitor mixture III (Calbiochem), 10 M trichostatin A, 10
mM nicotinamide, 50 mM butyric acid, pH 7.5) at 4 °C using an
Omni homogenizer (Omni International, Kennesaw GA) fol-
lowed by tip-probe sonication. The homogenate was centri-
fuged at 12,000 g for 15 min at 4 °C, and the supernatant was
precipitated with chloroform/methanol. Proteins were resus-
pended in 6 M urea, 2 M thiourea, 50 mM triethylammonium
biocarbonate, pH 8.0, and reduced with 10 mM DTT for 1 h at
25 °C followed by alkylation with 25 mM iodoacetamide for 30
min at 25 °C in the dark. The reaction was diluted 1:10 with 50
mM triethylammonium biocarbonate and digested with trypsin
(Promega, Madison WI; 50:1 substrate/enzyme) for 12 h at
30 °C, acidified to 2% (v/v) formic acid (FA), centrifuged at
12,000 g for 15 min, and the supernatant removed. Peptides
were desalted with hydrophilic-lipophilic balance solid phase
extraction columns (Waters Corp., Milford MA), eluted with
80% acetonitrile (ACN), 0.1% trifluoroacetic acid (TFA), and
dried by vacuum centrifugation. The entire procedure was per-
formed in duplicate.
Stable Isotope Labeling with Tandem Mass Tags (TMT) and
Peptide Enrichment—200 g of peptide from each group was
labeled with TMT (Thermo Scientific, San Jose CA) according
to the manufacturer’s instructions. The first replicate was
labeled as follows: TMT6-126: 0 min ischemia; TMT6-127: 0
min ischemiawith 10M splitomicin; TMT6-128: 20min ische-
mia; TMT6-129: 20 min ischemia with 10 M splitomicin;
TMT6-130: IPC; TMT6-131: IPC with 10 M splitomicin. The
second replicate was labeled in reverse. Peptides were resus-
pended in 50 mM MOPS, 10 mM NaH2PO4, 50 mM NaCl
(immunoprecipitation buffer; pH 7.2), supplemented with 50
l of anti-acetyl-Lys antibody-conjugated agarose (Immune-
Chem Pharmaceuticals, Canada), and rotated at 4 °C for 16 h.
The suspension was centrifuged at 1000 g for 1 min and the
supernatant collected. The resin was washed with 4 1 ml
immunoprecipitation buffer followed by 2 1 ml H2O. Lysine-
acetylated peptides were eluted with 2 200 l 0.2% (v/v) TFA
and purified using a C18/POROS Oligo R2/R3 reversed phase
(RP) micro-column, dried by vacuum centrifugation, and
stored at 20 °C. The supernatants from the IP flow-through
and each wash were combined and diluted 10-fold in 1 M gly-
colic acid in 80% ACN, 5% TFA (TiO2 loading buffer), as
described (65). This solution was incubated with 3 mg of TiO2
beads for 15 min at room temperature with gentle agitation.
The suspension was then centrifuged at 1000  g for 1 min.
Supernatant was removed, and beads were washed with TiO2
loading buffer followed by 80% ACN, 2% TFA and finally 20%
ACN, 0.2% TFA. Phosphopeptides were eluted with 1% ammo-
nium hydroxide, pH 11.3, and purified using a C18/POROS
Oligo R3 RP micro-column, dried by vacuum centrifugation,
and stored at20 °C. Enriched peptides were fractionated into
10 fractions for phosphopeptides and six fractions for acetyl-
Lys peptides, respectively, using TSKgel Amide-80 HILIC cap-
illary HPLC (66).
Reversed Phase Nano-Liquid Chromatography-Electrospray
Ionization Tandem Mass Spectrometry—Fractionated TMT-
labeled peptides were resuspended in 0.1% FA and separated by
reversed phase chromatography on an in-house 25-cm 
75-m Reprosil-Pur C18-AQ column (3 m; Dr. Maisch, Ger-
many) using an EASY nLC nano-HPLC (Proxeon, Odense,
Denmark). The HPLC gradient was 0–40% solvent B (solvent
A, 0.1% FA; solvent B, 95% ACN, 0.1% FA) over 120 min at a
flow of 250 nl/min. MS was performed using an LTQ-Orbitrap
Velos (Thermo Scientific). An MS scan (400–2000 m/z; MS
AGC1 106)was recorded in theOrbitrap set at a resolution of
30,000 at 400 m/z followed by data-dependent higher energy
collision dissociation (HCD)MS/MS analysis of the sevenmost
intense precursor ions. Parameters for HCD were as follows:
activation time 0.1 ms; normalized energy 45 (48 for phospho-
peptides); dynamic exclusion enabled with repeat count 1; res-
olution 7500; exclusion duration 30 s; maximum injection time
500 ms; and MSn AGC 1  105. Collected data are shown in
supplemental Table S1.
SILAC-labeled rat L6myoblast peptideswere resuspended in
0.5% acetic acid and separated by reversed-phase chromatogra-
phy on an in-house 40-cm 75-mReprosil-Pur C18-AQ col-
umn (1.9 m; Dr. Maisch) using an EASY nLC-1000 nano-
UHPLC (Proxeon). The HPLC gradient was 0–40% solvent B
(solvent A, 0.5% acetic acid; solvent B, 90% ACN, 0.5% acetic
acid) over 90 min at a flow of 250 nl/min. MS was performed
using a Q-Exactive (Thermo Scientific). An MS scan (300–
1750m/z; MSAGC3 106) was recorded in theOrbitrap set at
a resolution of 70,000 at 200 m/z followed by data-dependent
HCDMS/MSof the 12most intense precursor ions. Parameters
forHCDwere as follows: normalized energy 25; dynamic exclu-
sion enabled; resolution 35,000; exclusion duration 60 s, maxi-
mum injection time 120 ms, and MSn AGC 1 106.
Metabolite Quantification by Ion Pairing LC-SRM—Metab-
olites were extracted from 50 mg of tissue using a modified
boiling water extraction (67). Tissue was added to 150 l of 1
mMEDTA, 1mMHEPES, pH7.2, 4 °C and vortexed for 20 s. The
extract was boiled for 90 s, snap-frozen in liquid nitrogen, incu-
bated at 25 °C for 5 min, and then snap-frozen for 1 min. A
second incubation at 25 °C for 5 min was followed by incuba-
tion at20 °C for 1 h. The extract was incubated at 4 °C for 10
min and centrifuged at 20,000 g for 15min at 4 °C. Aliquots of
10 l of supernatant were analyzed in triplicate. Metabolites
were separated by reversed-phase chromatography on an in-
house 320-m  15-cm C18-AQ (3 m; Dr. Maisch) column.
TheHPLCgradientwas 0–20% solvent B over 5min, 20% for 15
min, 20–35% over 2.5 min, 35% for 2.5 min, 35–60% over 2.5
min, 60–95% over 2.5 min, 95% for 7.5 min (solvent A, 10 mM
tributylamine adjusted to pH4.9with 15mMacetic acid; solvent
B, methanol) at 6 l/min. MS was performed using a 5500
QTRAP with Turbo Ion spray source in negative ion MRM
mode. Parameters were as follows: GS1 20 p.s.i., curtain gas 20,
ion spray voltage4500 V, unit resolution. Acquisition was
performed by unscheduled MRM with a dwell time for each
transition set to 100 ms. Synthetic metabolites (Sigma) were
PTMCross-talk during Ischemia and Cardioprotection
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prepared in 10 mM stock solutions. Each metabolite was
directly infused into the mass spectrometer to select and opti-
mize transitions and to determine retention times. A 10 M
standard mixture was used for quality control and standard
curves. LLOQ andULOQwere assessed using a standard curve
at 10 concentrations from 100 pM to 10M defined as R2
0.95
and coefficient of variation 	20%. Standard additions experi-
ments were performed to validate metabolite identification
based on retention times, but no standard addition curves were
performed, and therefore relative quantification is presented
(supplemental Tables S2 and S3). All data analysis was per-
formed in MultiQuant Version 2.0 (AB Sciex).
Assessment of Splitomicin Stability by LC-SRM—To ensure
stability, splitomicin solutions were analyzed on a 1  50-mm
Luna Phenyl-Hexyl column (5 m; Phenomenex, Torrance,
CA). TheHPLC gradient was 0–100% solvent B over 5min and
100% for 5 min (solvent A, 0.1% acetic acid; solvent B, acetoni-
trile) at 100l/min.MSwas performed using a 5500QTRAP in
positive ion MRM mode. Parameters were as follows: GS1
20p.s.i., GS2 25p.s.i., curtain gas 20, ion spray voltage 5000V,
unit resolution. Acquisition was performed by unscheduled
MRM with a dwell time for each transition set to 100 ms. Spli-
tomicin (Sigma) was prepared in a primary stock solution of 10
mM in methanol. A 10 M solution was prepared in 50% meth-
anol, 0.1% acetic acid and used to select and optimize transi-
tions. A 10 M stock solution was prepared in Buffer A, and
LLOQ and ULOQ were assessed using a standard curve at five
concentrations from 1 nM to 10 M defined as R2
 0.95 (sup-
plemental Fig. S2A). Next, 10 M splitomicin in phosphate-
buffered saline, pH 7.5, was incubated at 37 °C. At the specified
times (0, 10, 20, 30, and 40min), 10l was removed and diluted
10-fold with Buffer A, and 10 l was immediately analyzed in
triplicate (supplemental Fig. S2B). Data analysis was performed
inMultiQuant Version 2.0 andmanually verified for peak qual-
ity (supplemental Fig. S2C). Following 20 min of incubation
(the specified baseline period for splitomicin in heart perfu-
sions prior to ischemia), the splitomicin concentration was
reduced from 10 to 5 M, which is 
10-fold the minimum
inhibitory concentration (68). At 40 min (the total time of the
longest Langendorff experiment, including ischemia), the con-
centration still remained above the minimum inhibitory
concentration.
Western Blotting—20 g of proteins were separated on 7-cm
SDS-polyacrylamide gels followed by wet transfer to PVDF
membranes. All blots were blockedwith 5% bovine serum albu-
min in Tris-buffered saline, 0.1% Tween 20 overnight at 4 °C.
Primary antibodieswere obtained fromCell SignalingTechnol-
ogy (Danvers, MA) and were as follows: anti-phospho-AMPK
(Thr-172), anti-AMPK, anti-phosphoacetyl-CoA carboxylase
(Ser-79); anti-phospho-Akt (Ser-473); anti-Akt, anti-phospho-
eIF4B (Ser-422); anti-eIF4B; anti-phospho-PKA substrate
(RRX(pS/pT). Secondary antibody was anti-rabbit IgG-HRP.
Equal protein loading was confirmed with Coomassie staining.
Analysis of Untargeted Mass Spectrometry Data—Raw data
were processed using Proteome Discoverer Version 1.3
(Thermo Scientific) into .mgf files. TMT-labeled myocardial
peptides were searched against the UniProt Rattus norvegicus
database (March, 2012: 41,696 entries) using MASCOT (Ver-
sion 1.12). SILAC-labeled L6 myoblast peptides were searched
against the UniProt R. norvegicus database containing an addi-
tional CKM entry containing a K369Q mutation, using
SEQUEST. Searches were performed with the following fixed
parameters: precursor mass tolerance of 10 ppm, product ion
tolerance of 0.02 Da, Cys-carboxyamidomethylation (TMT
peptides), and onemissed cleavage (three for acetyl-Lys enrich-
ments). For TMT peptides, searches were conducted with vari-
able modifications as follows: oxidation of Met; TMT labeling
of N termini and Lys; phosphorylation of Ser, Thr, and Tyr, and
acetylation of Lys. For SILAC peptides, variable modifications
were as follows: oxidation of Met; SILAC labeling of Arg and
Lys; and phosphorylation of Ser, Thr, and Tyr. Quantification
was performed using Proteome Discoverer with HCD MS/MS
reporter ion integration within a 50 ppm window for TMT
labeling and mass precision set to 2 ppm for SILAC labeling-
extracted ion chromatograms. All searches were filtered to a
	1% false discovery rate using Percolator (69). Phospho-RS
probabilities were used to calculate phosphorylation site local-
izations and a confident site reported as 
75% localization
probability (70). Phosphopeptide and acetyl-Lys peptide ratios
were normalized by the median ratios of nonmodified peptides
in each replicate. The global effect of ischemia, IPC, and split-
omicin on phosphorylation and acetyl-Lys was assessed by cal-
culating themedian of the duplicate averaged ratios. The inten-
sity of the observed reporter ions is known to influence
quantification accuracy (71). To account for this, the standard
deviation of the log2 ratios were calculated by ranking the
peptide intensities, and a sliding window script in R-project
using the Ringo Package enabled the calculation of a peptide
intensity-dependent standard deviation (72). The p values were
calculated using a two-sided t test and adjusted for multiple
testing using a false discovery rate approach (73) with the Stats
Package in R-project. Peptides were considered to be signifi-
cantly regulated if their ratios were 
2 S.D. (i.e. p value	0.05
following false discovery rate correction) and with a cutoff of
1.5-fold changewithin each replicate. A less stringent analysis
was also utilized to investigate regulated sites with only a cutoff
1.5-fold change. Fuzzy c-means cluster analysis was per-
formed using GProX (74). Kinase-substrate predictions were
made using Scansite (75), and pathway analysis was performed
with Ingenuity Pathway Analysis.
Peptide Synthesis—Peptide synthesiswas performedby Fmoc
chemistry (76). Briefly, peptides were prepared on a 0.25 mmol
scale by manual stepwise solid-phase synthesis using benzotri-
azol-1-yl-1,1,3,3-tetramethyluronium/N,N-diisopropylethyla-
mine on Rink-amide MBHA resin (substitution 0.78 mmol/g)
(Novachem, Collingwood, Australia). Amino acid (5 eq) and
N,N-diisopropylethylamine (10 eq)were employed in each cou-
pling step for 10min except for the synthesis of phosphorylated
peptides, where the coupling of Fmoc-Ser(PO(OBzl)-OH)-OH
was performed in 2.5 eq in the presence of 2-(7-aza-benzotria-
zole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate.
Fmoc deprotections were achieved with 3 3 min in an excess
of 20% piperidine in dimethylformamide, and capping was
achieved with 8% acetic anhydride in dimethylformamide for
10 min. Synthesis of lysine-acetylated peptides was achieved
with N-9-fluorenylmethoxycarbonyl-N-4-metyltrityl-lysine
PTMCross-talk during Ischemia and Cardioprotection
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(Fmoc-Lys(Mtt)-OH), which was deprotected after the final
assembly with 5 3 min in an excess of 2.5% TFA, 2.5% triiso-
propylsilane in chloroform followed by 3 3min in an excess of
10% N,N-diisopropylethylamine. Acetylation was performed
with 2 10 min in an excess of 8% acetic anhydride in dimeth-
ylformamide. The peptides were simultaneously deprotected
and cleaved from the resin in 2.5% triisopropylsilane, 2.5%H2O
in 95% TFA for 2 h. The solution was filtered and the filtrate
dried under nitrogen. Peptides were precipitated with diethyl
ether, resuspended in 50% ACN, lyophilized, resuspended in
0.1% TFA, and purified by HPLC on a 25-cm  15.2-mm C18
column (10 m; Phenomenex, Torrance, CA) using a GBC LC
1150 (Braeside, Australia). The HPLC gradient was 0–100%
solvent B (solvent A, 0.1%TFA; solvent B, 90%ACN, 0.1%TFA)
over 60min at a flowof 3ml/minwith 1.5-ml fractions collected
and UV detection at 210 nm. The nonacetylated peptides were
purified to 
99% (according to UV spectrophotometry),
although acetylated peptides contained aminor (9%) amount
of the nonacetylated form.
In Vitro Kinase/Phosphatase/Acetyltransferase/Deacetylase
Assays by nLC-SRM—Hearts were equilibrated for 15 min with
normoxic perfusion and then subjected to 20 min of ischemia
using Langendorff perfusion as described above. Tissue (500–
600 mg) was homogenized in 3-fold the weight (i.e. 1 mg/3 l)
of lysis buffer containing 20 mM Tris, 7.5 mM MgCl2, protease
inhibitor mixture, pH 7.4, at 4 °C. For kinase assays, lysis buffer
was supplemented with 5mMATP, phosphatase inhibitor mix-
ture III, and 10 M trichostatin A, 10 mM nicotinamide, and 50
mM butyric acid. For acetyltransferase assays, lysis buffer was
supplemented with 1 mM acetyl-CoA containing phosphatase
and deacetylase inhibitor mixtures. For phosphatase/deacety-
lase assays, lysis buffer was supplemented with 1 mM NAD.
Lysates were adjusted to pH 7.4, kept at 4 °C, and assays per-
formed within 30 min. Assays were performed as described for
kinase activity assay for kinome profiling (KAYAK) with minor
modifications (77, 78). Briefly, reactions were performed with
100 g of lysate and 250 pmol of substrate in a final reaction
volume of 20 l. Reactions were performed at 28 °C and
quenched with 20 l of 20% trichloroacetic acid (TCA) to pre-
cipitate the lysate following 0, 10, 20, 30, and 60 min. The reac-
tions were centrifuged at 16,000 g for 15 min at 4 °C; super-
natants were removed and diluted 1:1 with 0.2% TFA and
desalted with C18/R2/R3micro-columns. Peptides were resus-
pended in 100 l of 0.1% FA and 5 l analyzed by nLC-SRM.
Peptides were trapped on a 0.5-cm 300-mZorbax C18 col-
umn (5 m; Agilent Technologies, Palo Alto, CA) at 5 l/min
for 5 min using a nano-LC 2Dplus system (Eksigent, Dublin,
CA). Peptides were separated by reversed phase chromatogra-
phy on an in-house 30-cm  75-m Reprosil-Pur C18-AQ (3
m; Dr. Maisch) PicoFrit column (New Objective, Woburn,
MA). TheHPLCgradientwas 0–40% solvent B (solventA, 0.1%
FA; solvent B, 90% ACN, 0.1% FA) over 10 min at a flow of 250
nl/min. MS was performed using a 5500 QTRAP operated in
MRMmode. Parameters were as follows: GS1 20 p.s.i., curtain
gas 20 p.s.i., interface temperature 150 °C, ion spray voltage
2200 V, unit resolution. All four peptides were monitored
(unscheduled) for each reaction, and areas under the curve
were obtained using Skyline (79) and expressed as % substrate
conversion (areaproduct/(areasubstrate  areaproduct)). Transi-
tions were Savitzky Golay transformed and integration bound-
ariesmanually verified.All reactionswere analyzed in triplicate,
and those with coefficient of variation 
20% removed. Con-
trols were performedwithout addition of lysate, and incubation
of the substrates was at 28 °C for 60 min. No significant differ-
ences in substrate peak areas were observed. Five transitions/
peptide were utilized (supplemental Table S4) (80). Validation
of equimolar concentrations and transition selectivity were
determined by creating a quality control mix of the four pep-
tides (KXXS, KXXpS, AcKXXS, and AcKXXpS) and adding 50
fmol into a backgroundmyocardial lysate followed byTCApre-
cipitation, desalting, and analysis by nLC-SRM (supplemental
Fig. S3).
Immunoprecipitation of CKMWT, K369Q, and S372E and in
Vitro Kinase/Phosphatase and Deacetylase Assays—L6 myo-
blast cells were lysed in Nonidet P-40 lysis buffer (25 mM Tris,
137 mM NaCl, 10% glycerol, 1% Nonidet P-40, protease inhibi-
tor mixture, phosphatase inhibitor mixture, pH 7.4) and added
to protein G beads pre-incubated with anti-FLAGM2 antibody
(Sigma). Following incubation at 4 °C for 2 h, beads were
washed three times with Nonidet P-40 lysis buffer, three times
with PBS, and one time with either kinase buffer (20 mM Tris,
7.5 mMMgCl2, 5 mM ATP, 2 M CaCl2, 1.2 M calmodulin, pH
7.4) or deacetylase buffer (20 mM Tris, 4 mM MgCl2, 50 M
NAD,pH7.4).Forphosphataseassays,CKMwasfirstphosphor-
ylated by resuspending the beads in 20 l of kinase buffer con-
taining 80 units of CaMKII (New England Biolabs) and reacted
for 60 min at 30 °C. The beads were washed three times with
PBS and once with phosphatase buffer (20 mM Tris, 10 mM
MnCl2, pH 7.4), and heavy labeled samples were treated with 5
units of protein phosphatase 1 (PP1; New England Biolabs) for
30 or 60 min at 30 °C. For deacetylase assays, the heavy labeled
samples were resuspended in 20 l of deacetylase buffer con-
taining active FLAG-tagged SIRT1 (generously provided by Dr.
Amanda Brandon, Diabetes and Obesity Program, Garvan
Institute of Medical Research) and reacted for 30 or 60 min at
30 °C. Elution was performed with 8 g/30 l of FLAG peptide
in PBS, and light and heavy samples were pooled. Proteins were
separated by SDS-PAGE and stained with SYPRO Ruby
(Invitrogen) (supplemental Fig. S4) followed by in-gel tryptic
digestion. The experiment was performed in two biological
replicates.
Peptide Analysis by NMR Spectroscopy and CD—Peptides
were dissolved in 20 mM Tris-d11 (1 mM, 600 l H2O/D2O 9:1)
and adjusted to pH7.2.One-dimensional 1HNMRspectrawere
acquired on a Bruker Avance III 600 spectrometer (Bruker
Corp., Billerica,MA)withwater suppression (decoupling in the
presence of Scalar interactions) at 276–298 K. Two-dimen-
sional 1H NMR spectra were acquired on a Bruker Avance III
800 spectrometer with water suppression (decoupling in the
presence of Scalar interactions) at 276 K with a mixing time of
100 ms. 1H chemical shifts were referenced to 4,4-dimethyl-4-
silapentane-1-sulfonic acid ( 0.00 ppm) in water. Spectra were
processed using Topspin (Bruker) and manually analyzed with
Sparky Version 3.114. For CD analysis, peptides were dissolved
in 20mMTris (100M, 300l) and adjusted to pH 7.2. Analysis
was performed in a 1-mm quartz cell using a Jasco spectropo-
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larimeter (Easton, MD) ( 185–260 nm) at 50 nm/min with a
bandwidth of 1.0 nm. Each spectrum represented an average of
5 scans.
Data Availability—MS data have been deposited into the
PeptideAtlas repository (Identifier(s): PASS00283 for global
quantification of phosphorylation and acetyl-Lys following
ischemia and IPC; PASS00280 for quantification of phosphor-
ylation and acetyl-Lys cross-talk on CKM synthetic peptides;
and PASS00286 for quantification of dephosphorylation rates
of Ser-372 on human CKM with and without acetyl-Lys.
RESULTS
Myocardial Phosphorylation and Acetyl-Lys Networks—To
gain insights into signaling networks initiated by ischemia and
IPC, we quantified protein phosphorylation and acetyl-Lys
using isobaric labeling andMS/MS.Rat hearts (n 3per group)
were isolated using an ex vivo Langendorffmodel and subjected
to the following: (i) 0 min ischemia (0I); (ii) 20 min ischemia
(20I); and (iii) an IPC protocol (3 2 min I/R); all in the pres-
ence or absence of 10 M splitomicin (Fig. 1A) (22). Lysates
were trypsin-digested and peptides labeled with TMT. Phos-
pho- and lysine-acetylated peptides were enriched by TiO2
chromatography and immunoprecipitation, respectively, and
fractionated by HILIC. These fractions were analyzed by nano-
LC-MS/MS, and the entire procedure was repeated with
reverse labeling. Overall, 3101 protein groups were modified
(supplemental Table S1). Phosphorylation and acetyl-Lysmod-
ified 2546 and 728 protein groups, respectively, and 331 were
modified by both PTMs. Quantification at the protein level was
obtained for 694 protein groups (
1 peptide), with 298 and 361
of these containing either phosphorylation or acetyl-Lys sites,
respectively (supplemental Table S1). Protein abundance dis-
FIGURE 1. Phosphorylation and lysine acetylation analysis from ex vivomyocardial tissue. A, Langendorff perfused hearts were subjected to 0 or 20min
ischemia or IPC with or without the presence of 10 M splitomicin during 20 min of baseline (nonischemic) perfusion. Quantification was performed by TMT
isobaric labeling and sequential enrichment of lysine-acetylated peptides and phosphopeptides. Peptides were fractionated with HILIC and analyzed by
reversed phase nLC-MS/MS. B, histograms showing the distribution of phosphopeptides (purple, phospho), lysine-acetylated peptides (blue, AcetylK), and total
protein (orange) quantification expressed as log2 ratios relative to 0-min ischemia (0I).
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played very low variation (global log2 standard deviations mea-
sured at 0.31 and 0.34 for 20I and IPC, respectively), whereas
larger variations were observed for phosphopeptides (log2
standard deviations of 0.58 and 0.64 for 20I and IPC) and lysine-
acetylated peptides (log2 standard deviations of 0.48 and 0.59
for 20I and IPC), suggesting the myocardial response to acute
ischemia and IPC is dominated by changes in PTMs rather than
protein abundance (Fig. 1B). Perfusion of rat hearts with 10 M
splitomicin, without subsequent ischemia or IPC, increased
global acetyl-Lys by 10% (median ratio for 0I  splitomicin:
0I  1.1) and phosphorylation by 2.5%. 20I increased global
phosphorylation (median ratio for 20I:0I 1.04) and acetyl-Lys
(median ratio 1.05), and both were further increased by spli-
tomicin (median ratios compared with 0I of 1.08 for phosphor-
ylation and acetyl-Lys, respectively). IPC decreased global
acetyl-Lys by10% (median ratio for IPC:0I 0.91), and phos-
phorylation by 20% (median ratio for IPC:0I  0.83). Split-
omicin inhibited the reduction in acetyl-Lys (median ratio for
IPC splitomicin:0I 0.98) but not phosphorylation (median
ratio for IPC splitomicin:0I 0.81). For all conditions, total
protein abundance showedmedian ratios that indicated a	1%
change. These data suggest that ischemia and IPC influence
global acetyl-Lys and phosphorylation and also show thatmod-
ulation of acetyl-Lys with splitomicin can influence phosphor-
ylation indicative of cross-talk.
We quantified 7437 unique phosphopeptides (5605 phos-
phosites with 
75% localization probability; supplemental
Table S1), 346 (271 phosphosites; supplemental Table S1)
showing 
1.5-fold up-regulation and 194 (154 phosphosites)
showing 
1.5-fold down-regulation following 20I. Of the reg-
ulated phosphosites, 69 were significant with p value 	0.05 in
two independent experiments and 272 with p value	0.05 in at
least one experiment (two-sided t test). 402 unique phospho-
peptideswere regulated (299 phosphosites; supplemental Table
S1) by
1.5-fold following IPC (54 phosphosites with p value
	0.05 in two independent experiments and 197 with p
value 	0.05 in at least one experiment). Surprisingly, 267 of
these phosphopeptides were not regulated in 20I and were
highlighted as IPC-specific. 2898 unique lysine-acetylated pep-
tides were quantified, with 229 of these up- or down-regulated
(
1.5-fold) following either 20I (80 peptides) or IPC (159
peptides), whichwas consistentwith themedian ratios for these
conditions (Fig. 1B and supplemental Table S1).
The large scale data were interrogated using Ingenuity Path-
way Analysis (IPA) to identify pathways enriched in proteins
containing peptides modified by phosphorylation, acetyl-Lys,
or both (supplemental Fig. S5). Site-specific analysis also
allowed us to highlight PTM sites differentially regulated
between ischemia and IPC, and those influenced by splitomicin
to determine potential targets of cross-talk. Several pathways
were over-represented with regulated phospho- and acetyl-Lys
sites in both ischemia and IPC (supplemental Fig. S5), including
those associated with metabolism (fatty acid metabolism, TCA
cycle, glycolysis; Fig. 2A), as well as those involved in contrac-
tion and mitochondrial function (supplemental Fig. S6). Fatty
acid metabolism was enriched in both regulated phosphoryla-
tion and acetyl-Lys sites (Fig. 2A) during ischemia and IPC.
Several acetyl-Lys sites showed differential modification when
compared between 20I and IPC, for example Lys-214 of 3-ke-
toacyl-CoA thiolase (ACAA2) was significantly deacetylated
(
1.5-fold down-regulated;p value	0.05) but only during IPC.
Similar data were observed for mitochondrial trifunctional
enzyme subunits  and  (HADHA and HADHB), which
also display 3-ketoacyl-CoA thiolase activity. Splitomicin
attenuated deacetylation of ACAA2 Lys-214 (p value 	0.05),
and additional sites on HADHA. Deacetylation events were
observed more frequently in IPC than ischemia; however, this
effect was not global, andwe observed increased acetyl-Lys on a
number of sites, including additional sites on ACAA2 and
HADHB, suggestingmultiple acetylases/deacetylases are active
during IPC. Our results also show extensive modification of
proteins associated with mitochondrial dysfunction (supple-
mental Fig. S6), including several involved in redox homeosta-
sis and oxidative phosphorylation. IPC-specific deacetylation
was observed on more than 10 subunits of complex I; however,
none of these sites was attenuated by splitomicin. Complex V
was extensively modified with both phosphorylation and
acetyl-Lys. For example, increased acetylation of Lys-73 on
mitochondrial ATP synthase subunit O (ATP5O)was observed
with splitomicin treatment following both 20I and IPC. Addi-
tional pathways included the mitochondrial permeability tran-
sition pore (mPTP) complex and the contractile apparatus
(supplemental Fig. S6). Tropomyosin (TPM1), in particular,
contained numerous acetyl-Lys and phosphorylation sites that
were either significantly deacetylated or dephosphorylated dur-
ing IPC, with this effect significantly reversed by splitomicin,
which suggests co-regulation between these PTM.
Because splitomicin attenuates IPC (22) and our data identi-
fied pathways influenced by splitomicin in ischemia and IPC,
we wished to validate the functional basis for these changes.
The production and utilization of high energy phosphates are
metabolic processes intimately associated with ischemia and
IPC. These pathways (e.g. TCA cycle and glycolysis) were over-
represented as containing PTM sites responding to ischemia
and/or IPC (Fig. 2A; supplemental Fig. S5). We attempted to
validate our PTM data and pathway analysis using metabolo-
mics assays quantified by LC selected reaction monitoring
(LC-SRM) (supplemental Table S2). We monitored succinyl-
CoA (tricarboxylic acid cycle), fructose 1,6-bisphosphate (gly-
colysis), and creatine phosphate (mitochondrial high energy
phosphate essential for muscle contraction), as well as co-fac-
tors (NAD, NADH, and NADP) and lactate (Fig. 2B). Fructose
1,6-bisphosphate levels remained unaltered compared with 0I
in both 20I and IPC, irrespective of splitomicin treatment. Suc-
cinyl-CoA, however, increased 
5-fold following 20I, and this
was attenuated by splitomicin. Several acetyl-Lys sites were
identified on succinyl-CoA ligase (SUCLA2; Fig. 2A), yet only
Lys-88 was deacetylated during ischemia and ameliorated to
control levels by splitomicin in a manner consistent with the
metabolite data. No alterations in succinyl-CoA levels were
observed in IPC. Creatine phosphate was reduced by
40-fold
after 20I, irrespective of splitomicin treatment; however, split-
omicin in IPC resulted in creatine phosphate levels significantly
higher than those observed in IPC alone. We identified acetyl-
Lys sites in both muscle-type creatine kinase (CKM) and crea-
tine kinasemitochondrion type 2 (CKMT2) thatwere regulated
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by ischemia and IPC, and a subset of these responded to split-
omicin (supplemental Fig. S6). Ischemia induced accumulation
of NADH, yet NAD and NADP were unaltered relative to 0I.
As expected, lactate increased by 
40-fold after 20I; however,
splitomicin attenuated this significantly. Our data suggest this
is unrelated to lactate oxidation, because splitomicin did not
influence NADH levels.
Acetyl-Lys Influences Kinase Activation during Myocardial
Ischemia and IPC—Cross-talk between phosphorylation and
acetyl-Lys is likely mediated by kinases/phosphatases and/or
acetylases/deacetylases. To test this, we employed splitomicin
inhibition of lysine deacetylation and examined alterations in
signal pathways and their kinases. First, phosphopeptides up-
regulated by
1.5-fold in 20I were clustered into two groups as
follows: (i) those unaltered and (ii) those responding to split-
omicin (Fig. 3, A and B). These clusters were subjected to IPA
analysis (supplemental Fig. S5, B and C). Enriched pathways
containing proteins showing phosphorylation increases in 20I
thatwere ameliorated by splitomicin (Fig. 3B; supplemental Fig.
S5C) included AMPK signaling, insulin receptor signaling
FIGURE 2. Site-specific relative quantification ofmodified peptides and total protein (A) andmetabolites (B) from pathways highlighted in ischemia
and IPC, in the presence or absence of splitomicin. A, relative quantification (heat maps) of phosphopeptides (side bar, purple; phospho), lysine-acetylated
peptides (side bar, blue; AcetylK), and total protein (side bar, orange) with quantification expressed as log2 ratios relative to 0-min ischemia (0I) for selected
proteins clustered into the pathways “fatty acid metabolism,” “TCA cycle,” and “glycolysis.” B, selectedmetabolites quantified by LC-SRM; **, p	 0.001; *, p	
0.05; F-1,6-B, fructose 1,6-bisphosphate.
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(taken as AKT), and PKA signaling, although those that did
not respond to splitomicinwere predominantly associatedwith
metabolism (glycolysis/gluconeogenesis), aldosterone, and
actin signaling, ubiquitination, and extracellular remodeling
(supplemental Fig. S5B). Site-specific analysis was performed
on phosphopeptides regulated during 20I that responded to
splitomicin, and a subset of these mapped onto a network cen-
tered on AMPK, PKA, and AKT (Fig. 3C). Many substrates of
these kinases were regulated by 20I, and the phosphorylation
changes were ameliorated by splitomicin. This shows a role for
acetyl-Lys in regulating AMPK and AKT during myocardial
ischemia and is the first report to suggest a role for acetyl-Lys in
PKA regulation.
Western blotting confirmed the effects of splitomicin on
phosphorylation of AMPK, AKT, PKA, and their substrates
(Fig. 3, D and E; supplemental Fig. S7). For these experiments,
we generated hearts over a time course of ischemia (0, 2, 10, and
20 min ischemia; n  3) compared with 20 min free perfusion
(or “time control”; n  3). Splitomicin attenuated ischemia-
induced phosphorylation of Thr-172 on AMPK and Ser-473
on AKT, and this effect was more pronounced at 20I (Fig. 3D).
The downstream targets of AMPK (Ser-79 on ACC) and AKT
(Ser-422 on eukaryotic initiation factor 4B) were regulated sim-
ilarly to their respective kinases (Fig. 3D). Ser-79 phosphoryla-
tion inhibits ACC activity (carboxylation of acetyl-CoA tomal-
onyl-CoA); however, splitomicin in 20I did not result in a
concomitant decrease in acetyl-CoA, as determined by
LC-SRM (Fig. 3F; supplemental Table S3), despite the reduc-
tion in ACC phosphorylation. This suggests acetyl-Lys/
deacetylation may influence other enzymes with acetyl-CoA as
a substrate or product (e.g. 3-ketoacyl-CoA thiolase). Citrate
and other small molecules also allosterically modulate ACC
activity (81). Ischemic phosphorylation of PKA substrates
(RRX(pS/pT)) was also attenuated by splitomicin (Fig. 3E). This
correlated with splitomicin attenuation of ischemia-associated
increases in cAMP and provided evidence that PKA activation
may be regulated by acetyl-Lys/deacetylation viamodulation of
cAMP levels (Fig. 3G; supplemental Table S3).
We next investigated kinase activation in IPC. Phosphopep-
tides up-regulated by 
1.5-fold were functionally clustered
using IPA (supplemental Fig. S5D). Enriched pathways
included PKA,-adrenergic, and calcium signaling. A common
feature of these is MAPK signaling. We identified increased
phosphorylation of Tyr-185 in the activation loop of MAPK1
FIGURE 3. Kinase activation duringmyocardial ischemia is regulated by splitomicin-mediated inhibition of SIRT1-associated lysine deacetylation. A,
fuzzy c-means clustering of phosphopeptides differentially regulated between 0 min of ischemia (0I) (or 0 min of ischemia with splitomicin (0ISPLIT)) and
20-min ischemia (20I) but not attenuated following 20 min of ischemia in the presence of splitomicin. B, fuzzy c-means clustering of phosphopeptides
differentially regulated between 0min of ischemia (0I) (or 0min of ischemia with splitomicin (0ISPLIT)) and 20min of ischemia (20I), and attenuated by 20min
of ischemia with splitomicin (20ISPLIT). C, site-specific analysis of phosphopeptides (
75% localization probability) clustered in B regulated by 20I and
attenuated with splitomicin. Previously verified targets of AMPK (green), AKT (purple), and PKA (blue) with ischemia-induced increases in phosphorylation
attenuated by splitomicin (supplemental Table S1). Immunoblotting shows splitomicin attenuates ischemia-associated phosphorylation of Thr-172 AMPK,
Ser-473AKT, Ser-422 eIF4B, and Ser-79ACC (D) and PKA substrate, relative to 0min of ischemia and 20min of normoxic time control perfusion (TC) (E). Blots are
representative of n 3. F and G, relative quantification of acetyl-CoA (F) and cAMP (G) by LC-SRM inmyocardial tissue subjected to 20min of ischemia (20I) or
20min of ischemiawith splitomicin (20ISPLIT) expressed relative to 0min of ischemia (0I) (n 3). *, p value	 0.05 (two-side t test); ns, not significant. Error bars
show standard deviation.
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and Tyr-205 onMAPK3, both of which are associated with IPC
(82).We did not, however, observe altered phosphorylation of a
variety of PKC isoforms or substrates, including PKCA/PKCB
(Thr-497/Thr-550) and PKCD (Thr-505) nor the activation
autophosphorylation site of PKCD (Ser-643), the activation
C-terminal hydrophobic site of PKCD (Ser-662), or of PKCE
(Ser-729). Phosphopeptides up-regulated by 
1.5-fold in IPC
were next clustered into two groups as follows: (i) those unal-
tered, and (ii) those ameliorated by splitomicin, and each was
analyzed using IPA (supplemental Fig. S5, E and F). In contrast
to the results from 20I, PKA signaling was the most enriched
pathway unaffected by splitomicin treatment. Enriched path-
ways in the cluster containing phosphopeptides ameliorated by
splitomicin were predominantly associated with cell junction
signaling, aswell asAMPKsignaling (consistentwith the results
observed in 20I splitomicin).
Acetyl-Lys Promotes Dephosphorylation in a Basophilic
Kinase Motif—Our large scale data show strong evidence for
cross-talk as follows: phosphorylation and acetyl-Lys co-oc-
curred on many proteins, both PTM could be influenced by
splitomicin, and inhibition of lysine deacetylation influenced
the activation of three kinases (AMPK, AKT, and PKA) and
their downstream targets. We next examined the sequence
context and structural basis of cross-talk by determining the
proximity of PTM in tertiary structures (Protein Data Bank) of
45 proteins containing at least one confident ischemia or IPC-
regulated phosphorylation/acetyl-Lys site. Of these, 25 struc-
tures were available in the mammalian taxonomy containing at
least 80% sequence similarity to the Swiss-Prot R. norvegicus
sequence. Three proteins contained an amino acid substitution
at one site of PTM observed here. Fourteen proteins contained
at least one observed phosphorylated residue within 10 Å of
an identified acetylated lysine (supplemental Fig. S8). For
example, the solution structure of TPM1 highlights head-to-
tail interactions between individualmolecules where the C-ter-
minal phosphorylation on Ser-283 is in close proximity to an
N-terminal acetylation on Lys-12. Proximalmodificationswere
both adjacent (	5 amino acids) and distant (
5 amino acids) in
the primary sequence.
We next attempted to identify sequence motifs in which phos-
phorylation and acetyl-Lys were over-represented. MS/MS
sequences from PTM analysis of ischemia and IPC were com-
bined, and those showing evidence of modification by both
were considered further. We identified 50 peptides containing
the basophilic protein kinase motif KXXS, modified with either
acetyl-Lys or phosphoserine, but not both simultaneously (sup-
plemental Table S5). For example, CKM was modified by
acetyl-Lys at Lys-369 or phosphorylation at Ser-372, and both
sites were regulated by
1.5-fold following 20I. These changes
were partially attenuated by splitomicin (supplemental Table
S1).
To investigate this cross-talk and the rates of modification
induced by proximal PTM in the KXXS motif, we synthesized
the C-terminal peptide fromCKM (364EKKLEKGQSIDD375) as
four variants: (i) nonmodified (KXXS); (ii) phosphorylated at
Ser-9 (equivalent to Ser-372; KXXpS); (iii) acetylated at Lys-6
(Lys-369; AcKXXS); and (iv) acetylated at Lys-6 and phosphor-
ylated at Ser-9 (Lys-369 and Ser-372; AcKXXpS). We per-
formed in vitro kinase, phosphatase, acetyltransferase, and
deacetylase reactions on all variants and monitored the sub-
strates and products by nLC-SRM. Each variant was added into
a separate lysate generated following 20I. Quantification was
performed by comparing the area under the curve of the prod-
uct/substrate and expressed as percent substrate conversion/
min. Initially, kinase reactions were performed separately on
the two nonphosphorylated substrates ( acetyl-Lys) in the
presence of 5 mM ATP, phosphatase, and deacetylase inhib-
itors. Maximum phosphorylation of the KXXS substrate was
observed after 20 min (13% substrate conversion of KXXS to
KXXpS); however, no conversion of AcKXXS to AcKXXpS
was observed (Fig. 4A and supplemental Table S6). Dephos-
phorylation was next measured for the two phosphorylated
substrates ( acetyl-Lys) in the presence and absence of
phosphatase and deacetylase inhibitors. The KXXpS sub-
strate displayed 4% dephosphorylation to KXXS irrespective
of the presence of inhibitors, whereas the AcKXXpS sub-
strate showed 70% dephosphorylation to AcKXXS within 60
min (Fig. 4B and supplemental Table S6B) in the absence of
phosphatase inhibition, and 33% dephosphorylation to
AcKXXS in the presence of phosphatase inhibitors (Fig. 4C
and supplemental Table S6C). No changes in acetylation/
deacetylation were observed for any of the test peptides, even
in the absence of deacetylase inhibitors and in the presence
of 1 mM NAD, or with added 1 mM acetyl-CoA (supplemental
Tables S6, D and E). These results suggest that acetyl-Lys at
the “minus 3 amino acids” position (P-3) to the phosphory-
lation site promotes dephosphorylation. To further investi-
gate this, the C-terminal CKM phosphopeptide was synthe-
sized with the following: (i) Gln at Lys-6 (Lys to Gln; QXXpS)
to mimic acetyl-Lys; and (ii) Arg at Lys-6 (Lys to Arg;
RXXpS) to mimic the positively charged lysine. The RXXpS
substrate displayed 7% dephosphorylation to RXXS, whereas
the QXXpS acetyl-Lys mimic showed 43% dephosphor-
ylation to QXXS, providing further evidence for the promo-
tion of dephosphorylation by the presence of acetyl-Lys at
P-3 (Fig. 4D and supplemental Table S6F).
The hypothesis that dephosphorylation is promoted by prox-
imal acetyl-Lys requires the protein to be initially modified,
even transiently, at both sites. To investigate this, kinase and
phosphatase assays were performed using purified recombi-
nant enzymes. Scansite suggested that phosphorylation of
CKM Ser-372 is most likely catalyzed by CaMKII. CaMKII-
mediated reactions were performed using the KXXS and
AcKXXS CKM peptides. Maximum phosphorylation of the
KXXS substrate was observed after 60 min (98% substrate con-
version to KXXpS), whereas conversion of the AcKXXS sub-
strate proceeded at a slower rate (67% substrate conversion to
AcKXXpS by 60 min) (Fig. 4E and supplemental Table S6G).
These results show that simultaneous phosphorylation and
acetyl-Lys can occur in vitro. Next, antarctic phosphatase reac-
tions were performed on the two phosphorylated substrates
( acetyl-Lys). The KXXpS substrate displayed 65% dephos-
phorylation to KXXS, whereas AcKXXpS displayed a faster
dephosphorylation rate (91% substrate conversion to AcKXXS
within 60min) (Fig. 4F and supplemental Table S6H). Reactions
were also performed tk;4on the mimic phosphopeptides, with
PTMCross-talk during Ischemia and Cardioprotection
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the RXXpS substrate displaying slower dephosphorylation
compared with the QXXpS acetyl-Lys mimic (Fig. 4G and sup-
plemental Table S6I).
We next investigated acetyl-Lys-induced dephosphorylation
of full-length CKM. FLAG-tagged CKM wild-type (WT) and a
K369Q acetyl-Lys mimic were overexpressed in L6 myoblasts
grown in light and heavy stable isotope labeling by amino acids
in cell culture (SILAC) (Fig. 5A). Following anti-FLAG immu-
noprecipitation, enriched WT and K369Q mimic from both
light and heavy cells were subjected to in vitro CaMKII kinase
reactions. Excess kinase was removed, and the heavy labeled
WT and K369Q CKM were subjected to either 30- or 60-min
phosphatase reactions using recombinant PP1. Heavy labeled,
phosphatase-treated CKM was mixed with light labeled
non-phosphatase-treated CKM and digested with trypsin, and
the rate of dephosphorylation was measured by nLC-MS/MS.
Dephosphorylation rates were then determined by comparing
the phosphopeptide heavy/light ratios. WT CKM treated with
PP1 for 30 and 60mindisplayed very little dephosphorylation at
Ser-372 (	1.1-fold by 60 min or phosphorylation decrease of
only 3  2%; Fig. 5B; supplemental Table S7). The K369Q
acetyl-Lys mimic, however, displayed significant dephosphor-
ylation of Ser-372 by 30 min (phosphorylation decrease of 68%
 2%) and 
2-fold dephosphorylation following 60 min (Fig.
5B). These assays show that acetyl-Lys in theKXXS kinasemotif
reduces the rate of phosphorylation and promotes rapid
dephosphorylation.
To investigate whether phosphorylation influenced deacety-
lation, FLAG-tagged CKM WT and an S372E phospho-mimic
were overexpressed in L6 myoblasts grown in light and heavy
SILAC (Fig. 5C). Following anti-FLAG immunoprecipitation,
heavy labeledWT and S372E CKMwere subjected to 30 and 60
min of incubation with immunoprecipitated FLAG-tagged
SIRT1 deacetylase. Heavy labeled, deacetylase-treated CKM
was mixed with light labeled nontreated CKM and digested
with trypsin, and deacetylation was measured by nLC-MS/MS.
S372E CKM treated with SIRT1 displayed only minor deacety-
lation at Lys-369 (1.1-fold by 60 min, acetyl-Lys decrease of
10%  1%; Fig. 5D and supplemental Table S8). WT CKM,
however, displayed significant SIRT1-mediated deacetylation
of Lys-369 (1.6-fold by 60 min, acetyl-Lys decrease of 38 3%;
Fig. 5D). These data suggest that phosphorylation inhibits
SIRT1-mediated deacetylation within the KXXS motif. The
mutually exclusive nature of these two PTMs in the large scale
ex vivo dataset combined with the in vitro assays performed
here suggests that acetyl-Lys promotes dephosphorylation,
which in turn promotes deacetylation. The deacetylated form
of the motif can then be phosphorylated, which is consistent
with both our synthetic peptide and recombinant CKMprotein
kinase/phosphatase assays.
Acetyl-Lys Disrupts a Phosphate-Lysine Salt Bridge and
Induces Peptide Backbone Flexibility—We next investigated
the mechanism of acetyl-Lys-induced dephosphorylation. To
examine whether peptide backbone conformational changes
were induced by acetyl-Lys and/or phosphorylation, we ana-
lyzed the four CKM peptide variants by 1H NMR in the pres-
ence of 10% D2O in H2O at pH 7.2 (supplemental Fig. S9).
One-dimensional 1H NMR of the NH region of the four vari-
ants highlighted only minor chemical shift differences between
KXXS and AcKXXS with one additional peak arising from the
acetyl amide proton (supplemental Fig. S9,A andB). Phosphor-
ylation induced larger chemical shifts, and comparison of
KXXpS and AcKXXpS highlighted differences that indicated
significant changes in peptide backbone environments (supple-
mental Fig. S9, C andD). We investigated these by two-dimen-
sional 1H NMR total correlation spectroscopy (TOCSY) and
FIGURE 4. In vitro kinase and phosphatase assays demonstrate the kinetic effects of proximal phosphorylation and acetyl-Lys (AcetylK) on the CKM
peptide 364EKKLEKGQSIDD375 as follows: (i) nonmodified (KXXS); (ii) phosphorylated at Ser-9 (Ser-372; KXXpS); (iii) acetylated at Lys-6 (Lys-369;
AcKXXS); (iv) acetylated at Lys-6 and phosphorylated at Ser-9 (Lys-369 and Ser-372; AcKXXpS); (v) acetyl-Lys mimic Gln-6 and phosphorylated at
Ser-9 (K369Q and Ser-372; QXXpS); and (vi) acetyl-Lys-negative Arg-6 and phosphorylated at Ser-9 (K369R and Ser-372; RXXpS). A, kinase assay using
KXXS and AcKXXS added separately into lysates in the presence of phosphatase and deacetylase inhibitors. B, phosphatase assay using KXXpS and AcKXXpS
added separately into lysates in the absence of phosphatase anddeacetylase inhibitors.C,phosphatase assay usingKXXpS andAcKXXpS added separately into
lysates in the presence of phosphatase and deacetylase inhibitors.D, phosphatase assay using QXXpS and RXXpS added separately into lysates in the absence
of phosphatase deacetylase inhibitors. E, kinase assay using KXXS and AcKXXS with purified recombinant CaMKII. F, phosphatase assay using KXXpS and
AcKXXpS with purified recombinant antarctic phosphatase. G, phosphatase assay using QXXpS and RXXpS with purified recombinant antarctic phosphatase.
Peak areas of all variants were simultaneously monitored for each reaction using nLC-SRM to obtain % substrate conversion (areaproduct/(areasubstrate 
areaproduct)) at 0, 10, 20, 30, and 60 min (n 3).
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nuclear Overhauser effect spectroscopy (NOESY) (supplemen-
tal Fig. S10). An overlay of HA-HN TOCSY region of KXXpS
and AcKXXpS highlighted chemical shift differences in resi-
duesLys-6 to Asp-12, although Lys-3 to Glu-5 was unaltered
(Fig. 6A). Overlay of the HB-HNTOCSY and NOESY region of
AcKXXpS highlighted additional peaks in the TOCSY spec-
trum from residues I10-Asp-12 that are absent in the NOESY
region, indicating that the C-terminal region may be in two
conformations (Fig. 6B). These peaks were absent for KXXpS,
indicating a more rigid conformation. Multiple long range
1H-1H NOEs between the Lys-6 and Ser(P)-9 side chains in
KXXpS, which were absent in AcKXXpS, indicated that these
two residues are in close proximity (Fig. 6C) and provide evi-
dence for a phosphate-lysine interaction, which is inhibited by
acetyl-Lys. The rigidity of the KXXpS variant prompted us to
investigate the presence of secondary structure. Interrogation
of the NOESY spectrum revealed no HA-HN or HA-HB 1H-1H
NOEs between i and i 2 or 3 amino acids (indicative of -hel-
ices). Thiswas further confirmed by analysis of the four variants
with CD spectroscopy, which revealed no obvious secondary
structure (supplemental Table S9). Taken together, these
results suggest that the KXXpS variant is in a fixed conforma-
tion due to the formation of a phosphate-lysine salt bridge
(Fig. 6D). Acetyl-Lys inhibits the salt bridge and results in a
more flexible conformation, which is more accessible to
phosphatases.
DISCUSSION
Large scale acetyl-Lys and phosphorylation analysis in myo-
cardial ischemia and IPC identified PTM sites not previously
associated with injury or cardioprotection, and confirmed that
a specific response to each occurs at the signal level. Ischemia
induces extensive metabolic changes and acetyl-Lys is emerg-
ing as a regulator of metabolism (58, 63), cell protection, and
signal propagation (35, 38). Splitomicin treatment confirmed
acetyl-Lys is involved in myocardial ischemia and IPC and is
capable of cross-talk with phosphorylation-mediated signaling.
We confirmed that acetyl-Lys influences AMPK and AKT acti-
vation, and we also revealed a role in PKA regulation, most
likely via cAMP levels, although it remains unclear whether this
occurs through alteration of adenylate cyclase activity. Isch-
emia-induced phosphorylation of PKA site Ser-16 on phospho-
lamban was attenuated with splitomicin. Phospho-Ser-16
increases Ca2 uptake into the sarcoplasmic reticulum by dis-
rupting the inhibitory phospholambansarcoplasmic reticu-
lum-Ca2-ATPase complex (83, 84). In contrast, dephosphor-
ylation of phospholamban Ser-16/Ser-17 was observed in IPC
and was unaffected by splitomicin, along with other PKA tar-
gets, suggesting that the loss of cardioprotection associated
with splitomicin is independent of PKA. Numerous other tar-
gets of PKA were identified in the ischemia cluster responding
to splitomicin (e.g. Ser-156 on Bcl2 antagonist of cell death);
however, not all PKA targets responded similarly; for example,
FIGURE 5. In vitro phosphatase and deacetylase assays using SILAC-labeled, immunoprecipitated full-length CKM wild-type (WT), acetyl-Lys mimic
(K369Q), andphospho-mimic (S372E).A andC,overviewof the approach. FLAG-taggedWT, K369Q (A) andS372E (C) CKMwereoverexpressed in light (L) and
heavy (H) SILAC-labeled rat L6myoblasts. Following immunoprecipitation, CKM fromboth light andheavy labeled cellswas subjected toan in vitro kinase assay
with CaMKII (A). Heavy labeled CKM was subsequently subjected to phosphatase assays with PP1 for 30 or 60 min or an in vitro deacetylase assay with
immunoprecipitated FLAG-tagged SIRT1 for 30 or 60 min (C). Light and heavy labeled CKMwere eluted, mixed, and digested, and the rates of dephosphory-
lation or deacetylation were measured between light and heavy labeled peptides using nLC-MS/MS. B, quantification of the relative abundance of the SILAC
phosphopeptides GQSpIDDMIPAQK (WT) and KLEQGQSpIDDMIPAQK (K369Q) between light (untreated) and heavy (treated with PP1 for 30 or 60 min)
showing the rate of dephosphorylation expressed as log2(H/L). D, quantification of the relative abundance of the SILAC acetylated peptide KLEK(Ac)GQSID-
DMIPAQK (WT) and KLEK(Ac)GQEIDDMIPAQK (S372E) between light (untreated) and heavy (treated with SIRT1 for 30 or 60 min) showing the rate of deacety-
lation expressed as log2(H/L).
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cardiac myosin-binding protein C (MYBPC3) and cardiac tro-
ponin I (TNNI3) did not display increased phosphorylation in
20I nor reduced phosphorylation post-splitomicin treatment.
PKA phosphorylation of Ser-434 on SIRT1 increases deacety-
lase activity independently of NAD (39), suggesting SIRT1
and PKAmay regulate each other in a similar fashion to SIRT1
and AMPK (17), although unlike SIRT1/AMPK, the SIRT/PKA
relationship appears to be specific to ischemia. Although our
study used splitomicin to inhibit lysine deacetylation (22, 85),
we cannot unequivocally state that acetyl-Lys sites altered by
splitomicin are direct targets of SIRT1, nor whether other
SIRTs (or non-SIRT acetylases/deacetylases) may be affected.
For example, members of metabolic pathways containing
ischemia or IPC-induced changes in acetyl-Lysmay also be tar-
gets of SIRT3 (86). A detailed investigation of the IC50 values of
splitomicin on other deacetylases has not been performed.
Therefore, further validation of the regulated targets is required
to unequivocally pinpoint the role of SIRT1.
Phosphoproteomics showed no direct evidence for PKC acti-
vation during IPC. Despite this, we did observe increased phos-
phorylation of MAPK variants, consistent with the model of
IPC proposed in Ref. 82, which shows MAPK activation in IPC
is PKC-dependent. Alternatively, our model did not examine
I/R post-IPC. The PKC isoform implicated in signal complex
formation and IPC-mediated signaling (87) may be only tran-
siently activated during one of the cycles of I/R that constitute
IPC, or indeed it may be downstream of alternative signal path-
ways implicated in IPCor I/R; for example, PKCactivation itself
may be downstream of the ERK- and PI3K/AKT-associated
reperfusion injury salvage kinase pathway (88) and thus may
occur upon I/R after the protective IPC period is concluded.
Among the functional clusters containing members with
ischemia- and/or IPC-associated peptides that were influenced
by splitomicin were the contractile apparatus and mPTP. Reg-
ulation of contractility via phosphorylation has been demon-
strated on many proteins, including cardiac MYBPC3, TPM1,
troponins I and T, and myosin light chains 1 and 2. Our study
suggests acetyl-Lys may play a similar role in regulating the
contractile apparatus. For example, 28 acetyl-Lys sites were
identified on TPM1, and the proximity of acetyl-Lys and phos-
phorylation in head-to-tail structures of TPM1 suggested PTM
cross-talk is possible. Permeabilization and/or rupture of the
FIGURE 6. Analysis of CKM C-terminal peptide 364EKKLEKGQSIDD375: (i) phosphorylated at Ser-9 (Ser-372; KXXpS) or (ii) acetylated at Lys-6 and
phosphorylatedat Ser-9 (Lys-369andSer-372;AcKXXpS)by two-dimensional 1HNMRtotal correlation spectroscopy (TOCSY) andNOESY.Overlays of
HA-HNTOCSY region of acetylated (AcKXXpS) and nonacetylated (KXXpS) phosphopeptide are shown inA; HB-HN TOCSY andNOESY regions of the acetylated
phosphopeptide (AcKXXpS) are shown in B; side chainNOESY region of the acetylated (AcKXXpS) and nonacetylated (KXXpS) phosphopeptide is shown inC.D,
proposed conformation of the acetylated (AcKXXpS) and nonacetylated (KXXpS) phosphopeptide.
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mitochondrial membrane are linked to apoptotic and necrotic
cell death, which are associated with the mPTP in ischemic
injury. Themolecular composition of themPTP is still not fully
unraveled; however, proposed members include hexokinase 2,
ADP/ATP translocase (SLC25A), VDAC, CKMT2, mitochon-
drial apoptosis-induced channel, and peptidylprolyl isomerase
(89–91). Genetic studies, however, suggest some of these may
be dispensable for mitochondrion-associated cell death (92,
93). Recently, a novel composition of the mPTP has been pro-
posed (94) and includes ATP synthase, which suggests a dual
function for complex V as follows: (i) to produce energy and (ii)
to control cell death. We identified extensive phosphorylation
(
30 sites) and acetyl-Lys (33 sites) ofmPTPmembers,many of
which were regulated by ischemia and/or IPC. Splitomicin
ameliorated changes to acetylated peptides observed in ische-
mia and IPC from CKMT2 and SLC25A4, providing further
evidence of a widespread role for lysine deacetylation in medi-
ating the functional effects of ischemia and cardioprotection.
Another cluster of modified peptides belonged to proteins
involved in fatty acid metabolism. Unlike other tissues, the
myocardium produces 60–70% of its energy from fatty acid
oxidation. Ischemia results in lowered fatty acid oxidation and
an accumulation of fatty acid intermediates, which have
detrimental effects, including increased membrane instability,
arrhythmias, and increased infarct size. Reducing fatty acid
metabolism and promoting glucose oxidation has long been
known to provide cardioprotection (95). Our data show that at
least three enzymes (ACAA2, HADHA, and HADHB) with
3-ketoacyl-CoA thiolase activity contained post-translational
modifications that were induced by ischemia and/or IPC, and
ACAA2 acetyl-Lys was ameliorated in IPC by splitomicin. Inhi-
bition of 3-ketoacyl-CoA thiolase activity with trimetazidine
reduces -oxidation of fatty acids, promotes glucose oxidation,
and is a clinically effective anti-angina strategy (96). Differential
regulation of acetyl-Lys between ischemia and IPC on enzymes
displaying 3-ketoacyl-CoA thiolase activity provides insight
into the potential mechanism of cardioprotection.
Ischemia and IPC induced different changes to pathways
involved in metabolism and the production or utilization of
high energy phosphates. Conversion to anaerobic glycolysis
and production of lactate are well characterized in ischemia,
and we were surprised that splitomicin ameliorated this to a
significant extent. This suggests lysine deacetylation may be
beneficial in ischemia, which is contradictory to the loss of car-
dioprotection (22) induced by splitomicin in IPC. Ischemia
resulted in a similar rise in succinyl-CoA levels that were also
attenuated by splitomicin. This correlated with attenuated
deacetylation of at least one site in SUCLA2 suggesting a link
between acetyl-Lys and SUCLA2 activity. The large reduction
in creatine phosphate seen in both ischemia and IPC was only
attenuated by splitomicin during cardioprotection. These
results were consistent with several PTM on both CKM and
CKMT2, which again suggests that individual modification
sites may be critical for activity and be influential in contribut-
ing to the ischemic or cardioprotective phenotype. Changes in
the function of metabolic enzymes, such as CKMT2 and
SUCLA2, which utilize the high energy ATP pool that is rapidly
depleted during ischemia, may thus also be involved in mainte-
nance of ATP levels during IPC, with their functions at least
partially regulated by PTM.
Methylation in kinase motifs (97–101) and acetylation (102)
can occur mutually exclusively to phosphorylation. The struc-
tural basis for cross-talk is thought to be primarily via steric
hindrance and/or disruption of salt bridges or hydrogen bonds
between substrate and kinase (103). Contrary to this, acetyla-
tion of Lys-105 on CDC6 results in increased phosphorylation
of adjacent Ser-106 by cyclin-dependent kinases (45), and co-
modification of Lys-9 and Ser-10 on histone H3 also occurs
(104). Therefore, these PTMs can co-occur, and cross-talk may
mostly contribute to the kinetics of modification. A systematic
investigation of neighboring modifications in the protein
kinase KXXSmotif was undertaken to determine the structural
and kinetic constraints for cross-talk, because this motif was
over-represented in PTM regulated by ischemia and IPC.Mod-
eling of the motif using modified variants of the C-terminal
CKM peptide (acetylation of Lys-369 and phosphorylation of
Ser-372) showed that acetyl-Lys induced a 
10-fold dephos-
phorylation suggesting the recruitment of one or more phos-
phatases. This effect was also observed on full-length CKM
containing a K369Q acetyl-Lys mimic. Although the recruit-
ment of a phosphatase by acetyl-Lys has been suggested (46),
the molecular mechanism mediating this interaction has not
previously been investigated. Our data confirmed that the
KXXpS substrate contains a salt bridge interaction between
lysine and phosphate and a peptide backbone conformational
change compared with the doubly modified AcKXXpS sub-
strate. We propose that the Lys-Ser(P) interaction inhibits
phosphatase access, whereas acetylation neutralizes the charge,
inhibits salt bridge formation, and induces a flexible peptide
backbone facilitating phosphatase access.
In vitro SIRT1 deacetylase assays of CKMWT and an S372E
phosphomimic further suggest that once dephosphorylated,
the peptide is thenmore amenable to SIRT1-mediated deacety-
lationandhencemayonceagainbecomeavailable forphosphor-
ylation, depending on the rate of protein turnover and the avail-
ability of the kinase(s) and acetylase(s)/deacetylase(s) that drive
themodifications. Additionally, because the acetylase/deacety-
lase assayswithCKMsynthetic C-terminal peptides in complex
lysates did not show a similar effect, other acetylases/deacety-
lases (beyond SIRT1) may be involved in maintaining the PTM
balance in cardiac tissue during I/R and/or IPC.
Fifty peptides regulated in ischemia and/or IPC contained
the KXXS motif. We did not, however, observe evidence for
“reciprocal” regulation (i.e. increase in the acetylated form of a
peptide corresponding to a decrease in the phosphorylated
form or vice versa), nor did we see examples of any doubly
modified peptides in these data. For the structural and enzy-
matic evidence we observed to be physiologically relevant, the
doubly modified formmust be able to occur in vivo. We proved
that phosphorylation of both the CKMC-terminal peptide and
full-length protein can occur when lysine-acetylated, albeit at a
much slower rate than the native forms. These data, combined
with the rapid dephosphorylation of lysine-acetylated synthetic
peptide variants and full-length K369QCKM, suggest any dou-
bly modified forms within the KXXS motif would be highly
transient, and therefore it is not surprising that these were not
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observed as they are likely to be present at extremely low abun-
dance in the complex tissue lysates used for large scale analysis.
The lack of apparent reciprocal regulation is also likely to be
due to the sub-stoichiometric levels of these (and indeed most)
PTMs in the context of the overall protein abundance. This
means PTMcross-talk in this context is likely involved in signal
“dampening” or “tuning” (e.g. to protect against uncontrolled
signal pathway activation) rather than acting as a strict “on”/
“off” switch for every copy of the protein, or by generating an
extreme reversal of the PTMstate. Cross-talk in thismotif likely
provides amechanism tomodulate the level of signal activation
and thus ensure the maintenance of cellular balance. To our
knowledge, this is the first study to perform a detailed investi-
gation of intra-molecular cross-talk between phosphorylation
and acetyl-Lys within a kinase consensusmotif.We believe that
the observed mechanism represents a previously unexplored
level of regulation that is potentially widespread and is likely to
involve other signaling proteins and PTMs.
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